These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25802141)

  • 21. Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal "add-back" paradigms.
    Adashi EY
    Keio J Med; 1995 Dec; 44(4):124-32. PubMed ID: 8587224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Limited effect of gonadotrophin-releasing hormone analogues for patients with endometriosis].
    Seyer-Hansen M; Kruse C
    Ugeskr Laeger; 2012 Jun; 174(24):1671-3. PubMed ID: 22681992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
    Surrey ES
    Fertil Steril; 1999 Mar; 71(3):420-4. PubMed ID: 10065775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
    Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
    J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The need for add-back with gonadotrophin-releasing hormone agonist therapy.
    Studd J; Leather AT
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():1-4. PubMed ID: 8916978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy.
    Judd HL
    Am J Obstet Gynecol; 1992 Feb; 166(2):752-6. PubMed ID: 1531578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
    Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis.
    Wu D; Hu M; Hong L; Hong S; Ding W; Min J; Fang G; Guo W
    Arch Gynecol Obstet; 2014 Sep; 290(3):513-23. PubMed ID: 24728145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic uses of gonadotropin-releasing hormone analogs.
    Andreyko JL; Marshall LA; Dumesic DA; Jaffe RB
    Obstet Gynecol Surv; 1987 Jan; 42(1):1-21. PubMed ID: 3543765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis.
    DiVasta AD; Laufer MR
    Curr Opin Obstet Gynecol; 2013 Aug; 25(4):287-92. PubMed ID: 23770813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
    Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
    Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications.
    Rodriguez MI; Warden M; Darney PD
    Am J Obstet Gynecol; 2010 May; 202(5):420-8. PubMed ID: 20031112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
    Donnez J; Donnez O; Dolmans MM
    Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroids (uterine myomatosis, leiomyomas).
    Lethaby A; Vollenhoven B
    Clin Evid; 2005 Dec; (14):2264-82. PubMed ID: 16620489
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis.
    Della Corte L; Barra F; Mercorio A; Evangelisti G; Rapisarda AMC; Ferrero S; Bifulco G; Giampaolino P
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):759-768. PubMed ID: 32597340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women.
    Sener AB; Seçkin NC; Ozmen S; Gökmen O; Doğu N; Ekici E
    Fertil Steril; 1996 Feb; 65(2):354-7. PubMed ID: 8566261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention.
    Schindler AE
    Gynecol Endocrinol; 2009 Dec; 25(12):765-7. PubMed ID: 19905992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.